Development and improvement of anti-gout property from aqueous-methanol extract of morinda elliptica using central composite design
Xanthine oxidase (XO) is a key enzyme in hyperuricemia, catalyzing the oxidation of hypoxanthine to xanthine and then to uric acid. Excess serum accumulated with uric acid leads to a type of arthritis known as gout. In this study, development of process conditions for XO inhibitory activity from...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English English |
| Published: |
AENSI Publications
2014
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/36413/ http://irep.iium.edu.my/36413/ http://irep.iium.edu.my/36413/1/734-743_Parveen_.pdf http://irep.iium.edu.my/36413/4/36413_Development%20and%20improvement%20of%20anti-gout_SCOPUS.pdf |
| Summary: | Xanthine oxidase (XO) is a key enzyme in hyperuricemia, catalyzing the oxidation of
hypoxanthine to xanthine and then to uric acid. Excess serum accumulated with uric
acid leads to a type of arthritis known as gout. In this study, development of process
conditions for XO inhibitory activity from the leaves of Morinda elliptica was
performed by using 70% methanol. Optimization of process parameters such as
extraction temperature (ºC), extraction time (h), agitation speed (rpm) and ratio of
sample to solvent (1g/ml) at five levels was carried out using central composite design
(CCD) for the improvement of activity to treat gout. The analysis of variance
demonstrated that the model F-value of 18.31 showed the significance of the model
with R2 of 97.71%. The analysis revealed that the percentage of XO inhibitory activity
was improved at 32 ºC, 30 h, 125 rpm and 1 g/15 ml of solvent. The optimized
conditions were verified and the percentage of XO inhibitory activity obtained was
88.93%. The results are encouraging to formulate food, nutraceutical or pharmaceutical
products incorporating natural xanthine oxidase inhibitor (XOI), an alternative to
irresponsive synthetic XOI. |
|---|